<DOC>
	<DOCNO>NCT01952080</DOCNO>
	<brief_summary>This open label , 4-cohort study . Non-randomized subject receive teduglutide 3 active cohort . An attempt make enroll additional subject observational cohort receive standard care . Three dos teduglutide investigate 12 week . All subject screen prior start treatment ( SOT ) establish baseline characteristic include safety , eligibility nutritional support parameter .</brief_summary>
	<brief_title>A Pharmacokinetic , Safety , Pharmacodynamic Study Teduglutide Pediatric Subjects With Short Bowel Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Short Bowel Syndrome</mesh_term>
	<criteria>Key Current history SBS result major intestinal resection , ( eg , due necrotizing enterocolitis , midgut volvulus , intestinal atresia , gastroschisis ) least 12 month prior screen Short bowel syndrome require parenteral nutrition/intravenous ( PN/IV ) support Stable PN/IV support least 3 month prior enrollment base upon opinion investigator Key Serial transverse enteroplasty bowel lengthen procedure perform within past 3 month Unstable absorption due cystic fibrosis , untreated Hirschsprung 's disease know DNA abnormality ( ie , Familial Adenomatous Polyposis , Fanconi syndrome ) Evidence obstruction upper gastrointestinal ( GI ) series do within 6 month prior screen Major gastrointestinal surgical intervention within 3 month prior screen ( insertion feed tube endoscopic procedure allow )</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Short Bowel Syndrome</keyword>
	<keyword>SBS</keyword>
	<keyword>Pediatric SBS</keyword>
</DOC>